Cachexia (Treatment)

FDA Approves Somatotropin for AIDS Wasting

Published in AIDS Weekly, September 9th, 1996

The U.S. Food and Drug Administration (FDA) granted accelerated approval for the use of somatotropin (Serostim), a human growth hormone, to treat AIDS wasting syndrome, according to an August 23, 1996, FDA Talk Paper.

The terms of the accelerated approval require additional clinical trials to confirmed reported findings and investigated whether somatotropin improves patients' physical performance. Since December of 1994, more than 300 patients have already received Serostim under a treatment IND. Serono Laboratories, Inc., Randolph, Massachusetts, has agreed to distribute the drug.

The findings of an earlier trial indicated that patients treated...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1996-09-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry